Amicus' Pompe circumstance changes as FDA lifts clinical hold
This article was originally published in Scrip
Executive Summary
The US FDA has removed the clinical hold on Amicus Therapeutics' AT2220 (1-deoxynojirimycin HCI), which is being developed to treat Pompe disease. Amicus' lead programme, Amigal (migalastat HCl), is in Phase III for the treatment of Fabry disease and is partnered with GlaxoSmithKline.